Low Incidence of Myocardial Recovery After Left Ventricular Assist Device Implantation in Patients with Chronic Heart Failure.

Mancini, Donna; Beniaminovitz, Ainat; Levin, Howard R.; Catanese, Katharine A.; Flannery, M.; DiTullio, Marco R.; Savin, S; Cordisco, Marie Elena; Rose, Eric A.; Oz, M.C.

doi:10.1097/01823246-199910010-00006

Cited by 92 publications

(145 citation statements)

References 0 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…For patients with ischemic cardiomyopathy, LVAS implantation does not achieve suffi cient recovery of myocardial function. 7 Thus, we assume that the increased cardiac function was due to cell transplantation, although further clinical studies must be done to analyze the effects of cell transplantation. After LVAS implantation, decreased LV distension contributed to the reduced cell diameter and lower BNP, in accordance with previous reports.…”

Section: Discussionmentioning

confidence: 99%

Combined autologous cellular cardiomyoplasty using skeletal myoblasts and bone marrow cells for human ischemic cardiomyopathy with left ventricular assist system implantation: Report of a case

et al. 2009

View full text Add to dashboard Cite

Myocardial regeneration therapy shows great promise as a treatment for heart failure. We recently introduced combined autologous cellular cardiomyoplasty with skeletal myoblasts and bone marrow cells as a treatment for human ischemic cardiomyopathy. We report the results of our first clinical trial of this technique, used to treat a patient with severe heart failure caused by ischemic cardiomyopathy who was being managed with a left ventricular assist system (LVAS). After combined cell transplantation, the patient showed signs of improved cardiac performance and angiogenesis, and reduced fibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined autologous cellular cardiomyoplasty using skeletal myoblasts and bone marrow cells for human ischemic cardiomyopathy with left ventricular assist system implantation: Report of a case

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Aber auch bei Patienten mit Myokarditis oder gar bei einer dilatativen Kardiomypathie (DCMP), die mit einem Langfrist-Unterstützungssystem versorgt worden sind, wird in der Literatur von einer 5-bis 25%igen Chance der Myokarderholung berichtet, abhängig von Faktoren wie u. a. Alter, Diagnose, Länge der bestehenden Erkrankung oder Vollstän-digkeit der Entlastung des Herzens wäh-rend der VAD Therapie [50,51,52,53,54,55]. Falls es zu einer Myokarderholung gekommen ist, kann man mit entsprechender Erfahrung und auch ausgearbeiteten "Weaning"-Protokollen das VAD-System wieder explantieren.…”

Section: Vad-weaning Und -Explantationunclassified

Fortschritte bei implantierbaren mechanischen Kreislaufunterstüzungssystemen

Krabatsch

Schweiger

Stepanenko

et al. 2011

Herz

View full text Add to dashboard Cite

In recent years, ventricular assist devices (VAD) supporting the left (LVAD), the right (RVAD) or both ventricles (BVAD) have rapidly emerged as the standard of care for advanced heart failure patients. Both the numbers and ages of patients in which they are used are rising worldwide, especially when used as a permanent support (bridge to destination, BTD). Due to the continuing lack of donor organs, these devices now represent a viable alternative to bridge patients to transplantation (BTT), with a 1-year survival rate of 86%. BTD, especially in long-term support, might be a valid, and the sole, option for those patients in whom heart transplantation is contraindicated. Patient selection, pre- and intra-operative preparation, as well as the timing of VAD implantation are important factors critical to successful circulatory support. While BTT remains the goal in the majority of patients, the number of permanent VADs (i. e. BTD) is rising significantly. Although explantation of a VAD system as a bridge to recovery (BTR) can be considered in only a small number of patients, it represents a very special part of this therapy modality.

show abstract

“…In Kombination mit Steroiden und Ciclosporin führt MMF zu einer deutlichen Reduktion der Mortalität und der Abstoßungshäufigkeit innerhalb des 1. Jahres nach Transplantation [16,29]. Daher wurde bei den meisten Patienten Azathioprin (Imurek ® ) durch MMF (CellCept ® ) ersetzt.…”

Section: Immunsuppressionunclassified

“…Durch die Entlastung kam es offenbar zu einer Regeneration des Myokards, so dass das System bei einigen Patienten entfernt werden konnte. Die Mechanismen dieser Remodeling-Vorgän-ge sind jedoch noch unbekannt; daher lässt sich bisher nicht vorhersagen, bei welchen Patienten es zu einer Erholung der Myokards kommt und bei welchen nicht [7,10,16,19]. Bei Patienten mit einer akuten Myokarditis ist ein Unterstützungssystem eine anerkannte Therapie bis zur möglichen Erholung der Herzfunktion.…”

Section: Indikationenunclassified